Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

Also called NCT01617681

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01617681
  • EudraCT 2011-005991-40
Other papers using this trial's data
  • Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase Current medical research and opinion, 2021-12 DOI, PubMed 34543161

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Brazil, France, Germany, Guatemala, Hungary, Italy, Lithuania, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01617681. Randomized; triple masking; primary purpose treatment. Start 2012-11-08 (actual); primary completion 2017-01-24 (actual). Results posted on 2017-09-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
Condition
Pediatric Hypertension With or Without CKD
Intervention (Drug)
VAL489
Intervention (Drug)
VAL489 matching placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01617681
Content hash
6294318962e86b753c587b9a1216a9d34b6fce9c784f0b0b498ba3f2290a22f7